Sponsored content brought to you by
The next evolution of CAR T therapy isn’t happening in a cleanroom—it’s happening inside the patient. For years, ex vivo CAR T has defined the field: extract T cells, engineer them, reinfuse them. This is effective, but complex, time-intensive, and logistically demanding. Each step introduces variability, from cell handling to expansion efficiency, while requiring specialized infrastructure that can limit scalability. In contrast, in vivo CAR T is gaining traction as a more streamlined alternative, especially by using lentiviral vectors (LVVs) to deliver genetic instructions directly into the body.
“By being able to produce CAR T cells directly in the body, you mitigate a lot of the room for error,” explains Annie Huang, senior manager of content marketing at GenScript ProBio. “Without dealing with cell culture and all the associated handling, you reduce variability and complexity.”
CAR T therapy works by equipping T cells with engineered receptors that recognize and attack disease. Traditionally, that engineering happens outside the body through a multi-step workflow that can take weeks. In vivo approaches eliminate those steps by delivering genetic material directly to T cells, enabling them to be reprogrammed in place.
This shift is not just about efficiency. By reducing reliance on external processing, in vivo CAR T has the potential to improve consistency and expand access for patients who might not be able to wait for or access complex manufacturing pipelines. Expanding the development and testing of in vivo CAR T therapies, though, depends on giving
researchers and companies easy access to the tools they need.
Why ProBio’s tLVV platform stands out
ProBio is advancing the field with a purpose-built LVV platform designed specifically for in vivo CAR T applications, “known as tLVV—a T cell binder present on the LVV envelope, which serves as a ‘T cell specifically targeting LVVs’ or ‘T cell re-targeting LVVs’.” says Huang. “Our tLVV platform optimizes membrane fusion capability, which leads to higher functional titers and maximized transduction efficacy.” The system integrates a proprietary transfer plasmid backbone with customer-provided binders and fusogens. The binder acts as a targeting mechanism, directing where the viral particle attaches, while the fusogen enables entry into the desired cell. This modular approach allows developers to tailor targeting strategies while leveraging ProBio’s optimized backbone and supporting plasmid systems.
Importantly, ProBio’s platform is engineered to address a key concern in in vivo delivery: off-target effects. By incorporating a proprietary backbone designed to silence unintended CAR expression, the system helps reduce the risk of incorrect binding and antigen masking—issues that can compromise efficacy or lead to resistance. This design focus supports more controlled and efficient transduction in vivo.
LVVs also offer a significant advantage in terms of acceptance by regulators. “From a regulatory perspective, LVV is more mature,” says Jingyuan Zhang, PhD, content marketing specialist at ProBio. “So, there’s less barrier when applying it to in vivo approaches.”
Because LVVs are already widely used in ex vivo CAR T therapies, they come with an established safety and manufacturing track record. This familiarity can help streamline regulatory pathways, allowing developers to focus innovation on delivery and targeting rather than introducing entirely new vector systems.
From design to scaled delivery
Once administered, the LVV delivers CAR genes directly into T cells, initiating an immune response against disease targets. However, achieving reliable performance in vivo requires overcoming challenges such as envelope protein variability, vector aggregation, and binding inefficiencies.
ProBio addresses these issues through optimized plasmid design, refined manufacturing workflows, and integrated development services that support consistency from early-stage research through clinical production. The company’s new facility in Hopewell, New Jersey, further strengthens this capability, providing scalable viral-vector manufacturing tailored to in vivo CAR T and gene therapy applications. This facility can also manufacture non-viral versions of gene therapy.
Combined with end-to-end support—from construct design to CMC and GMP production—ProBio’s tLVV platform positions developers to move more efficiently from concept to clinic. As in vivo CAR T continues to evolve, such integrated solutions may play a crucial role in translating promise into practical, accessible therapies.
Explore More: www.probiocdmo.com/webinars/gene-cell-therapy-categories
The post Rewriting the Rules of CAR T Delivery appeared first on GEN – Genetic Engineering and Biotechnology News.